Table 6.
Cytotoxic activity of designed compounds
| Compound | R1 | R2 | R3 | pIC50 (M) | IC50 (μM) |
|---|---|---|---|---|---|
| a. | -H | -Br | -H | 5.1581 | 6.9490 |
| b. | -H | -NO2 | -H | 5.2999 | 5.0131 |
| c. | -F | -H | -H | 5.3681 | 4.2843 |
| d. | -Cl | -H | -H | 5.1022 | 7.9040 |
| e. | -F | -H | -F | 5.4049 | 3.9362 |
| f. | -Cl | -H | -Cl | 4.9666 | 10.7985 |
| g. | -Br | -Br | -H | 5.1224 | 7.5440 |
| h. | -F | -F | -H | 5.8668 | 1.3590 |
| i. | -Cl | -Cl | -H | 4.9438 | 11.3808 |
| j. | -NO2 | -H | -H | 5.478 | 3.3265 |
| k. | -Br | -H | -Br | 5.1535 | 7.0224 |
| l. | -NO2 | -H | -NO2 | 5.7351 | 1.8403 |
| Template (compound 20) | -Br | -H | -H | 5.257 | 5.5330 |
| Doxorubicina | 5.23 ± 0.2 |
Key: a Abo-Elanwar et al. [16]